R&DWe are opening a new era
in the global new drug development.

Our New Drugs

  • 캄토벨

    Achievements

    Category Chong Kun Dang’s 1st New Drug
    2001 Won 2nd prize in the Patent Technology Award

    Won the grand prize in the Korean New Drug
    Award by Korea Drug Research Association
    2003 Won the grand prize in Health Industry
    Technologies Exposition Korea

    Novel topoisomerase-I inhibitor for small cell lung cancer and ovarian cancer,
    Camtobell

    ·
    Korea’s 8th new drug, 3rd new anti-cancer drug approved by KFDA
    ·
    Launched in Korea in 2004
    ·
    Significantly low rate of hematological adverse effects
    (leukopenia, thrombocytopenia, anemia) and gastric, neurological symptoms
  • 듀비에

    Achievements

    Category Chong Kun Dang’s 2nd New Drug
    2014 Won the Grand Prize in the 15th Korean New
    Drug Award by Korea Drug Research Association
    2015 Won the Jang Young-shil Award by Korea
    the Minister of Science and Technology

    Novel PPAR- γ agonist for diabetes, DuvieTM

    ·
    Korea’s 20th new drug, the 1st insulin sensitizer developed in Korea
    ·
    Launched in Korea in February 2014
    ·
    Significant blood glucose-lowering efficacy and safety profile
    ·
    Statistically significant improvement in metabolic syndrome and lipid profile vs. placebo
    ·
    DuvieTM was sold approximately 9 mil. USD in 2015